Clinical trials: Advanced Malignant Tumors
Neoplasms, Breast Neoplasms
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
This study is comprised of two portions: a Phase 1 portion and a Phase 2 portion. The Phase 1 portion is a single-country, non-randomized, open label, clinical trial which will evaluate the safety, tolerability, preliminary…
- Trial name
- NCT01684215
- Testing
- PD-0332991, letrozole
- Where
- 16 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Pfizer
Solid Tumor
A Study in Participants With Advanced Solid Tumors
This trial is testing ramucirumab (LY3009806) administered to Chinese participants with advanced solid tumors that are resistant to standard therapy or for whom no standard therapy is available.
- Trial name
- NCT01682135
- Testing
- Ramucirumab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Neoplasms
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm.
- Trial name
- NCT03416335
- Testing
- DSP-0509, DSP-0509, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sumitomo Pharma America, Inc.
Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
This phase Ib/II trial studies the side effects and best dose of EMB-01 when given together with osimertinib in patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (advanced or…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05498389
- Testing
- EMB-01, Osimertinib
- Where
- 3 sites in United States, China
- Volunteers
- 115 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
ADVANCED SOLID TUMORS
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic study of PM01183 for patients with advanced solid tumors
- Trial name
- NCT00877474
- Testing
- PM01183
- Where
- 2 sites in United States, Spain
- Volunteers
- 30 people
- Sponsor
- PharmaMar
NSCLC, SCLC
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.
- Conditions
- NSCLC, SCLC, CRPC, ESCC
- Trial name
- NCT04686682
- Testing
- JAB-8263
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
- Trial name
- NCT01298323
- Testing
- Patient outreach, Vandetanib
- Where
- 66 sites in Australia, Austria and 18 more
- Volunteers
- 205 people
- Sponsor
- Sanofi
Advanced Solid Tumor
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
This is a multi-center, open label, phase Ib/II clinical study of AK109 and AK104 to evaluate the safety, tolerability, effectiveness, pharmacokinetic characteristics in advanced solid tumors .
- Trial name
- NCT05142423
- Testing
- AK109+AK104
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Akeso
Advanced Solid Tumors
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
The purpose of this study is to determine if IMC-A12 is safe for participants, and also to determine the best dose of IMC-A12 to give to participants.
- Trial name
- NCT00785538
- Testing
- IMC-A12
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Gastrointestinal Stromal Tumors
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
This study consists of Dose escalation part and Expansion part. In Dose Escalation Part, the maximum tolerated dose of combination of pimitespib and imatinib in patients with gastrointestinal stromal tumors (GIST) who are judged…
- Trial name
- NCT05245968
- Testing
- Pimitespib, Imatinib, Sunitinib
- Where
- 14 sites in Australia, China and 3 more
- Volunteers
- 78 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Advanced Solid Tumor
SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors.
- Trial name
- FIRST (NCT05525559)
- Testing
- ET0038
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
Pancreatic Cancer
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
This Phase 1b/2 study will examine the effects of the study drugs, avelumab, binimetinib and talazoparib when given in a 2 (doublet) or 3 (triplet) drug combination, in patients with locally advanced or metastatic RAS-mutant…
- Trial name
- NCT03637491
- Testing
- Avelumab, Binimetinib, Talazoparib
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
Advanced Solid Tumors
Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors
This is an open-label, multicenter, dose-escalation phase I study to assess the safety, tolerability and preliminary efficacy of KN044 in participants with all advanced solid tumors who are not able to have current standard…
- Trial name
- NCT04126590
- Testing
- KN044
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma)…
- Trial name
- ReFocus202 (NCT07359820)
- Testing
- Lirafugratinib
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 30 people
- Sponsor
- Elevar Therapeutics
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Cancer, Solid Tumors
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.
- Conditions
- Cancer, Solid Tumors, Advanced Solid Malignancies
- Trial name
- NCT00973076
- Testing
- AZD8055
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Advanced Malignant Solid Tumor
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors.
- Trial name
- NCT04165590
- Testing
- Plasmodium immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CAS Lamvac Biotech Co., Ltd.
Advanced or Metastatic Solid Tumors
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
This is an open label, two-part, multicenter, multi-regional phase I trial to investigate the safety, tolerability, and PK of KGX101 monotherapy and combination therapy with Envafolimab in patients with advanced or metastatic…
- Trial name
- NCT06074497
- Testing
- KGX101- Cohort -1, KGX101- Cohort 1, KGX101- Cohort 2
- Where
- 3 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Kangabio AUSTRALIA LTD PTY
Solid Tumor, Cancer
DXP-106 in Solid Tumor Patients.
The goal of this clinical trial is to evaluate the safety and tolerability of DXP-106 in Chinese patients with advanced solid tumors. The main questions it aims to answer are: For Part I: 1.
- Trial name
- DXP-106 (NCT07532018)
- Testing
- DXP-106
- Where
- 4 sites in China
- Volunteers
- 54 people
- Sponsor
- Singlomics Biopharmaceuticals Zhuhai Co., Ltd.